» Articles » PMID: 10973252

Mutations in ATP6N1B, Encoding a New Kidney Vacuolar Proton Pump 116-kD Subunit, Cause Recessive Distal Renal Tubular Acidosis with Preserved Hearing

Overview
Journal Nat Genet
Specialty Genetics
Date 2000 Sep 6
PMID 10973252
Citations 168
Authors
Affiliations
Soon will be listed here.
Abstract

The multi-subunit H+-ATPase pump is present at particularly high density on the apical (luminal) surface of -intercalated cells of the cortical collecting duct of the distal nephron, where vectorial proton transport is required for urinary acidification. The complete subunit composition of the apical ATPase, however, has not been fully agreed upon. Functional failure of -intercalated cells results in a group of disorders, the distal renal tubular acidoses (dRTA), whose features include metabolic acidosis accompanied by disturbances of potassium balance, urinary calcium solubility, bone physiology and growth. Mutations in the gene encoding the B-subunit of the apical pump (ATP6B1) cause dRTA accompanied by deafness. We previously localized a gene for dRTA with preserved hearing to 7q33-34 (ref. 4). We report here the identification of this gene, ATP6N1B, which encodes an 840 amino acid novel kidney-specific isoform of ATP6N1A, the 116-kD non-catalytic accessory subunit of the proton pump. Northern-blot analysis demonstrated ATP6N1B expression in kidney but not other main organs. Immunofluorescence studies in human kidney cortex revealed that ATP6N1B localizes almost exclusively to the apical surface of -intercalated cells. We screened nine dRTA kindreds with normal audiometry that linked to the ATP6N1B locus, and identified different homozygous mutations in ATP6N1B in eight. These include nonsense, deletion and splice-site changes, all of which will truncate the protein. Our findings identify a new kidney-specific proton pump 116-kD accessory subunit that is highly expressed in proton-secreting cells in the distal nephron, and illustrate its essential role in normal vectorial acid transport into the urine by the kidney.

Citing Articles

Monoclonal nanobodies alter the activity and assembly of the yeast vacuolar H-ATPase.

Knight K, Park J, Oot R, Khan M, Roh S, Wilkens S bioRxiv. 2025; .

PMID: 39829782 PMC: 11741422. DOI: 10.1101/2025.01.10.632502.


Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis.

Boyer O, Ould Rabah M, Preka E Paediatr Drugs. 2024; 26(6):649-657.

PMID: 39325135 DOI: 10.1007/s40272-024-00651-9.


Dominantly acting variants in ATP6V1C1 and ATP6V1B2 cause a multisystem phenotypic spectrum by altering lysosomal and/or autophagosome function.

Carpentieri G, Cecchetti S, Bocchinfuso G, Radio F, Leoni C, Onesimo R HGG Adv. 2024; 5(4):100349.

PMID: 39210597 PMC: 11465052. DOI: 10.1016/j.xhgg.2024.100349.


A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.

Li Z, Alshagawi M, Oot R, Alamoudi M, Su K, Li W Oncotarget. 2024; 15:575-587.

PMID: 39145534 PMC: 11325586. DOI: 10.18632/oncotarget.28638.


Human V-ATPase function is positively and negatively regulated by TLDc proteins.

Oot R, Wilkens S Structure. 2024; 32(7):989-1000.e6.

PMID: 38593795 PMC: 11246223. DOI: 10.1016/j.str.2024.03.009.